InspireMD (NYSE:NSPR) Shares Up 2% - Should You Buy?

InspireMD, Inc. (NYSE:NSPR - Get Free Report)'s stock price shot up 2% during mid-day trading on Tuesday . The company traded as high as $2.05 and last traded at $2.00. 62,647 shares traded hands during trading, a decline of 43% from the average session volume of 109,290 shares. The stock had previously closed at $1.96.InspireMD Trading Up 2.0%The stock's 50-day moving average is $2.22 and its 200-day moving average is $2.35. The stock has a market cap of $84.74 million, a price-to-earnings ratio of -2.67 and a beta of 0.64. Hedge Funds Weigh In On InspireMDHedge funds have recently made changes to their positions in the business. Huntleigh Advisors Inc. boosted its position in InspireMD by 5.8% during the 2nd quarter. Huntleigh Advisors Inc. now owns 124,228 shares of the company's stock worth $282,000 after purchasing an additional 6,821 shares during the period. Raymond James Financial Inc. lifted its stake in shares of InspireMD by 28.9% during the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company's stock worth $101,000 after purchasing an additional 10,000 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of InspireMD by 45.0% in the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company's stock worth $91,000 after buying an additional 11,778 shares during the period. Rosalind Advisors Inc. boosted its position in shares of InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company's stock worth $5,196,000 after buying an additional 14,109 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of InspireMD in the first quarter valued at about $38,000. Hedge funds and other institutional investors own 44.78% of the company's stock. InspireMD Company Profile (Get Free Report)InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.Featured StoriesFive stocks we like better than InspireMD3 Grocery Stocks That Are Proving They Are Still Essential Warner Bros. Sale Rumors Heat Up: What Investors Need to KnowProcter & Gamble NYSE: PG Pulls Back After Shaky GuidanceFrom Science Project to Solvent: WeRide’s 761% Revenue SurgeEnergy and Oil Stocks ExplainedWill the S&P 500 Rally in December? These 3 Signals Point to a Big Move AheadThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in InspireMD Right Now?Before you consider InspireMD, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here